Foghorn Therapeutics Inc. (FHTX)
- Previous Close
5.05 - Open
5.20 - Bid 4.95 x 100
- Ask 5.35 x 100
- Day's Range
5.09 - 5.38 - 52 Week Range
2.70 - 9.97 - Volume
45,662 - Avg. Volume
161,853 - Market Cap (intraday)
219.64M - Beta (5Y Monthly) 3.13
- PE Ratio (TTM)
-- - EPS (TTM)
-2.34 - Earnings Date May 8, 2024 - May 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.75
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
foghorntx.comRecent News: FHTX
Performance Overview: FHTX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FHTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FHTX
Valuation Measures
Market Cap
218.79M
Enterprise Value
29.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.32
Price/Book (mrq)
--
Enterprise Value/Revenue
0.87
Enterprise Value/EBITDA
-0.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-288.17%
Return on Assets (ttm)
-19.53%
Return on Equity (ttm)
--
Revenue (ttm)
34.16M
Net Income Avi to Common (ttm)
-98.43M
Diluted EPS (ttm)
-2.34
Balance Sheet and Cash Flow
Total Cash (mrq)
234.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-48.87M